share_log

Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Maintains $62 Price Target

Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Maintains $62 Price Target

Chardan資本維持對rocket pharmaceuticals的買入評級,維持目標價62美元
Benzinga ·  2024/11/12 05:50  · 評級/大行評級

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $62 price target.

Chardan Capital分析師Geulah Livshits繼續維持對rocket pharmaceuticals(納斯達克:RCKT)的買入評級,維持62美元的目標價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論